Introduction {#s1}
============

Microglia are resident immune cells of the CNS, which are specialized to respond to both immunological and neuronal stimuli. Early work in situ suggested that calcium activity was critical for key microglial functions such as motility, cytokine release, and receptor trafficking/diffusion ([@bib11]; [@bib16]; [@bib33]). However, more recent in vivo studies have demonstrated that spontaneous calcium signaling is nearly absent in microglia ([@bib3]; [@bib5]; [@bib23]). Such observations downplay the potential utility of calcium signaling for microglial function.

Over the past two decades of astrocyte calcium research, it has become clear that microdomains (soma, major branches, and minor branches) have exquisitely different calcium signaling properties, with the smallest sub-compartments of the cell having the most abundant calcium signaling ([@bib27]). Microglial processes are well known to dynamically extend and retract as they survey the brain microenvironment ([@bib10]; [@bib20]; [@bib37]). To date, microglial processes have not been extensively evaluated for their calcium activity in vivo, nor has any assessment been performed in the awake animal. Herein, we evaluated microglial soma and process calcium signaling in awake mice using two-photon microscopy.

One of the key questions in microglial research is the extent to which microglia functionally respond to neuronal activity in the mature brain. Testing a high signal-to-noise GCaMP variant (GCaMP6s) and a membrane-tethered GCaMP variant (Lck-GCaMP6f), we find that microglia have very infrequent calcium activity in their processes under basal conditions. However, microglial process calcium signaling is attuned to neuronal activity changes, with both neuronal hypoactivity and hyperactivity triggering increases in microglial process calcium signals. By contrast, microglial somatic calcium changes may represent a disease signature as somatic calcium changes were only evident in longitudinal epilepsy development. Our work reveals that microglia have highly dynamic process calcium activity during network activity shifts, most closely associated with processes undergoing extension or outgrowth.

Results {#s2}
=======

Spontaneous microglial calcium activity in Lck-GCaMP6f and cytosolic GCaMP6s mice {#s2-1}
---------------------------------------------------------------------------------

Microglial calcium activity has been frequently described in situ, with limited studies performed in vivo. We first assessed microglial calcium activity in acute window preparations (24 hr after surgery), testing the utility of two sensors: GCaMP6s and Lck-GCaMP6f ([@bib19]; [@bib28]). The GCaMP6s sensor was chosen for its ideal signal-to-noise ratio, while the Lck-GCaMP6f sensor was chosen to detect potential fast calcium transients, or transients highly localized to fine processes, as demonstrated in astrocytes ([@bib28]). Both sensors were targeted to microglia using the CX3CR1^CreER-IRES-eYFP^ mouse line. It is important to note that the low-level, but constitutive eYFP signal from this mouse was detected alongside the dynamic GCaMP6 calcium signal. Spontaneous calcium activity was studied in the awake, head-restrained animal ([Figure 1A](#fig1){ref-type="fig"}), using two-photon microscopy to assess microglia in layer I and II/III of somatosensory cortex. Microglial calcium activity was present in both the Lck-GCaMP6f mouse and the cytosolic GCaMP6s mouse ([Figure 1B and C](#fig1){ref-type="fig"}). However, the higher fluorescence amplitude and slower decay kinetics in the GCaMP6s animal made this fluorophore ideal for studying calcium activity in thin microglial processes. On average, GCaMP6s reported calcium transients with a 50% greater amplitude and a 60% increase in signal area ([Figure 1D](#fig1){ref-type="fig"}). For these reasons, we could detect calcium events in a greater percentage of microdomains in the GCaMP6s animal ([Figure 1C](#fig1){ref-type="fig"}). Therefore, we adopted GCaMP6s mice for our studies of microglial calcium activity. It should be mentioned, however, that Lck-GCaMP6f mice do report unique phenomenon not observed in the GCaMP6s mouse. Specifically, small amplitude, widespread, and temporally coordinated calcium events can be observed in the parenchyma of Lck-GCaMP6f mice using a grid-based analysis ([Figure 1E](#fig1){ref-type="fig"}).

![Spontaneous microglial calcium activity reported in the Lck-GCaMP6f and cytosolic GCaMP6s mouse.\
(**A**) Imaging setup: in vivo two-photon imaging of microglial calcium activity in the awake, head-restrained animal. (**B**) Average intensity projection images and microglial ∆F/F calcium traces reported by Lck-GCaMP6f or cytosolic-GCaMP6s mice with a magnified cell. ∆F/F traces are from the soma and processes of a representative cell using manual segmentation. (**C**) Percentage of active microdomains reported by each sensor. (**D**) Maximum amplitude and signal area reported by each sensor (bar: mean ± SEM; dots: individual microdomains; 1-Way ANOVA with Sidak's post-hoc comparison). (**E**) The Lck-GCaMP6f mouse reports microglial calcium activity that is widespread, coordinated, and low-level throughout the parenchyma (Eii), compared to periods of relative inactivity (Ei). Scale bar: 50 µm (**B and E**). \*p\<0.05, \*\*\*\*p\<0.0001. N = 4 Lck-GCaMP6f mice, N = 8 Cyto-GCaMP6s mice.\
Figure 1---source data 1.Microglial spontaneous calcium.](elife-56502-fig1){#fig1}

Notably, as immune cells, microglia respond to a variety of stimuli, including injury and inflammation. We next assessed whether studying microglial calcium activity soon after surgery in the acute window preparation (\>24 hr) resulted in similar calcium activity patterns to a chronic window animal (4 weeks after surgery; [Figure 2A](#fig2){ref-type="fig"}). The morphology of cortical microglia was highly similar in acute and chronic window studies (Sholl analysis, [Figure 2B](#fig2){ref-type="fig"}). Despite the similarities in morphology, microglial process calcium activity was significantly greater in acute window preparations, while somatic calcium activity levels were indistinguishable ([Figure 2C--G](#fig2){ref-type="fig"}). Approximately one-third of microglia somata exhibited calcium activity in layer I (55--75 µm depth) and layer II/III (150--170 µm depth) in both the acute and chronic window preparations ([Figure 2E](#fig2){ref-type="fig"}). In the acute window preparation, most microglia were either completely inactive (24% of cells surveyed) or had spontaneous activity in under half of their processes (40% of cells surveyed; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). However, one month after surgical recovery, the proportion of active processes dropped further for both layer I microglia (56% to 35%), and layer II/III microglia (54% to 41%, [Figure 2E](#fig2){ref-type="fig"}). Additionally, highly active processes sporadically observed across microglia in the acute window preparation were not maintained in the chronic window animal ([Figure 2G](#fig2){ref-type="fig"}). Notably, in the chronic window animal, baseline recordings from the same region were stable over 3 successive days of recording ([Figure 2H](#fig2){ref-type="fig"}). For these reasons, we performed all other studies in chronic window mice to avoid any potential confounds associated with post-surgery microglial activation ([@bib39]).

![Spontaneous microglial calcium activity differs between acute and chronic window preparations.\
(**A**) Timeline of acute and chronic window imaging and animal training. (**B**) eYFP average intensity images of microglia morphology in acute and chronic window preparations. Sholl analysis of microglial morphology (n = 50 microglia per group; two-way ANOVA). (**C--D**) Microglial ∆F/F calcium traces from the soma and processes of a representative cell in an acute window animal (**C**), or two representative cells in a chronic window animal (**D**), using manual segmentation. (**E**) Percent of active microdomains (Fisher's exact test). (**F**) The amplitude recorded from microdomains (one-way ANOVA with Sidak's post-hoc comparison). (**G**) The calcium signal area recorded from microdomains (one-way ANOVA with Sidak's post-hoc comparison). Cumulative distribution curves for Layer I and Layer II/III process calcium signal areas. (**H**) Microglia soma and process calcium signal areas recorded over 3 successive days in chronic window animals. Scale bars: 50 µm (**B**). Grouped data represent the mean ± SEM; dots represent microdomains (**F and G**); dashed lines represent individual animals (**H**). The number of animals and microdomains surveyed is described in (**E**). \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.\
Figure 2---source data 1.Acute and chronic window spontaneous microglial calcium.](elife-56502-fig2){#fig2}

Isoflurane anesthesia increases microglial process extension and calcium activity {#s2-2}
---------------------------------------------------------------------------------

To date, it is unclear whether neuronal activity influences microglial calcium signaling. We first assessed whether general anesthesia impacts microglial calcium signaling. After recording baseline calcium activity in the awake animal, we introduced isoflurane anesthesia via nose cone ([Figure 3A](#fig3){ref-type="fig"}). Importantly, the isoflurane concentration chosen for maintenance (1.5--2% in oxygen) is intended to mimic strong sensory blockade during surgery and is higher than the concentration typically used during anesthetized imaging (0.5--1.5%). Our studies of neuronal activity indicate that 1.5--2% isoflurane maintenance can reduce excitatory calcium signaling by 91 ± 0.11% in the somatosensory cortex (AAV.CaMKIIa.GCaMP6s.WPRE transfected mice, layer II/III of somatosensory cortex; [Figure 3B--D](#fig3){ref-type="fig"}). In response to strongly reduced neuronal activity, microglia demonstrate an increase in process calcium activity ([Figure 3E--G](#fig3){ref-type="fig"} and [Figure 3---Video 1](#fig3video1){ref-type="video"}). Increased microglial process calcium activity is first detected 6 min after anesthesia ([Figure 3H](#fig3){ref-type="fig"}) and reaches peak levels approximately 10--20 min after isoflurane induction ([Figure 3G](#fig3){ref-type="fig"}). At their peak, microglial processes display a 290 ± 29% increase in average ∆F/F calcium signal area ([Figure 3G](#fig3){ref-type="fig"}). Despite strong increases in process calcium activity, somatic calcium signaling remained unaffected in microglia under general anesthesia, with no changes in the proportion or signal area of somatic events ([Figure 3G](#fig3){ref-type="fig"}). These results provide early evidence that microglial compartments could have distinct calcium-associated functions.

![Isoflurane anesthesia increases microglial calcium activity.\
(**A**) Timeline of experiment in a chronic window animal. (**B--D**) Control studies of excitatory neuronal calcium activity before and after isoflurane induction. (**B**) Representative ∆F/F traces of somatic calcium activity from layer II/III CaMKIIa neurons in one animal. (**C**) A heatmap of CaMKIIa somatic calcium activity from 60 representative somatic ROIs in one animal under awake and isoflurane conditions. (**D**) Baseline-normalized neuronal calcium activity under isoflurane (Paired t-test; dots: one animal) showing an average 91% drop in calcium signaling in the first 10 min of isoflurane maintenance (1.5--2%). (**E--H**) Microglial calcium responses to isoflurane from a cohort of chronic window GCaMP6s;Cx3Cr1^CreER-eYFP^ mice (see also: [Figure 3---Video 1](#fig3video1){ref-type="video"}). (**E**) Representative ∆F/F traces under awake and isoflurane conditions from the depicted microglial cell using threshold-based segmentation. (**F**) A heat map of microglial calcium activity from 60 threshold-segmented process territories surveyed across multiple microglia in a single field of view from a representative animal. (**G**) Microdomains active and their signal areas from baseline through anesthesia (two-way ANOVA; \*Dunnett's post-hoc vs. baseline; ^\#^somata vs. processes) using the threshold-segmentation approach for quantification. Dashed lines represent the averaged data from each of five animals, while solid lines represent the mean ± SEM from the N = 5 animals. (**H**) Microglial process territory calcium activity was binned by minute across all territories studied (311 to 379 territories detected in different imaging periods). The mean minute-by-minute signal area during the baseline period (0.385 ∆F/F∙s, dashed line) was compared to minute-by-minute calcium signal areas during isoflurane exposure (one-sample t-test comparison to the baseline average), indicating significant calcium changes in microglial processes are detectable 6 min after exposure . (**I**) After masking the soma, uniform thresholding of the average intensity image by period shows increasing total process area during isoflurane exposure (dashed lines: individual animal; solid lines: group mean ± SEM; one-way ANOVA with Dunnett's post-hoc vs. baseline). (**J**) Microglial process calcium activity under isoflurane was studied by motility/morphology characteristics. As displayed in the cartoon, microglial motility/morphology was categorized as processes that retracted under isoflurane, processes that remained stable, or processes that extended, showing new areas of outgrowth. Exact criteria and methodology are provided in the methods and displayed further in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. After subdividing processes based on motility characteristics, the percentage of processes exhibiting calcium activity is displayed (horizontal bars, Fisher's exact test) along with the signal magnitude (one-way ANOVA with Tukey's post-hoc test; the number of sampled regions fitting each criterion is provided near the bar; mean ± SEM). Scale bars: 50 µm (**B**), 10 µm (**E**). N = 4 AAV-CaMKIIa-GCaMP6s mice (**A--C**), N = 5 GCaMP6s;Cx3Cr1^CreER-eYFP^ mice (**D--G**). \*p\<0.05, \*\*^,\ \#\#^p\<0.01, \*\*\*p\<0.001, \*\*\*\*^,\ \#\#\#\#^p\<0.0001.\
Figure 3---source data 1.Microglial calcium activity during isoflurane.](elife-56502-fig3){#fig3}

In accordance with our previous studies in the awake animal, general anesthesia increases microglial process outgrowth ([@bib18]). At the isoflurane concentration used, we observed a gradual increase in total process area co-occurring with increased process calcium activity ([Figure 3I](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In situ, microglial process motility has been strongly associated with calcium activity ([@bib17]; [@bib21]). In vivo, we observe that microglia have a unique morphological response to isoflurane, characterized by extension and outgrowth of sub-branchlets from main processes ([Figure 3J](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These areas of new process extension/outgrowth exhibit the largest calcium signals and the highest association with calcium activity ([Figure 3J](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). On the other hand, processes with little-to-no motility (termed 'stable' processes) had significantly less associated calcium activity and signal magnitude. Processes that retracted during isoflurane exposure also exhibited much lower associated calcium activity and signal magnitude ([Figure 3I](#fig3){ref-type="fig"}). Our observations suggest that calcium activity increases under isoflurane are most directly associated with process extension and sub-branchlet outgrowth.

Kainate administration leads to acute and longitudinal increases in microglial calcium signaling {#s2-3}
------------------------------------------------------------------------------------------------

We additionally used kainate, an excitatory receptor agonist and chemoconvulsant, to determine if strong increases in neuronal activity can alter microglial calcium signaling. In a first cohort of chronic window mice, we recorded microglial calcium activity at baseline and soon after kainate-induced generalized seizures (i.p. kainate model; [@bib35]) in awake mice ([Figure 4A](#fig4){ref-type="fig"}). A first generalized seizure began between 45 and 75 min after kainate administration. Seizure generalization involves activation of cortical neuronal populations. In neuronal studies (AAV.CaMKIIa.GCaMP6s.WPRE transfected mice), kainate increased excitatory calcium activity both soon after administration (15--30 min) and after the first observed seizure (55-fold increase in signal area; [Figure 4B and C](#fig4){ref-type="fig"}). After the first observed seizure, microglial process calcium activity was increased by 360 ± 26%, with a greater proportion of processes exhibiting calcium activity (32% to 73%; [Figure 4D--F](#fig4){ref-type="fig"}). Despite strong increases in process calcium signaling, microglial somatic signaling did not increase significantly as measured through average signal area; however, there was an increase in the proportion of somata exhibiting calcium activity (29% to 44%; [Figure 4E and F](#fig4){ref-type="fig"}). During kainate-induced seizures, the predominant motility behavior was process extension, with process area increasing across the parenchyma ([Figure 4G](#fig4){ref-type="fig"}). These findings demonstrate that both an approach to rapidly decrease neuronal activity (isoflurane) and an approach to rapidly increase neuronal activity (kainate) similarly result in large-scale increases in microglial process calcium activity. In addition, both approaches resulted in increased microglial process territory and were insufficient to alter microglial somatic calcium activity.

![Increased microglial process calcium activity immediately following the observation of kainate-induced seizures.\
(**A**) Outline of the experimental timeline. Mice experienced a first seizure 45--75 min after kainate injection, which marked the beginning of imaging during periods labelled as 'kainate.' (**B--C**) CaMKIIa excitatory neuronal calcium activity (AAV.CaMKIIa.GCaMP6s.WPRE transfection) in the somatosensory cortex before and after kainate administration. (**B**) Representative ∆F/F traces at baseline, and after the first observed generalized seizure (45--75 min after kainate). (**C**) Signal areas derived from CaMKIIa somata in layer II/III (1-Way ANOVA with Dunnett's post-hoc comparison to baseline). (**D-G**) Microglial calcium activity (GCaMP6s;Cx3Cr1^CreER-eYFP^) in the awake animal at baseline and after the first kainate-induced generalized seizure. (**D**) Representative ∆F/F traces from a microglial cell using threshold-based ROI detection. (**E**) The percentage of active microdomains under each condition (Fisher's exact test). (**F**) Summary of calcium signal area values at baseline and after the first generalized seizure (two-way ANOVA with post-hoc comparison between kainate and baseline), using the threshold-segmentation approach for quantification. (**G**) Two-color, average intensity images of microglial morphology at baseline and after kainate-induced seizures, suggesting overall process extension. Changes in process area are quantified between conditions (paired t-test). Scale bars: 50 µm (**B**), 10 µm (**D**). Grouped data represent the mean ± SEM; dots represent individual neuronal somata (**C**) or individual microdomains (**F**); dashed lines represent individual animals (**G**). N = 3 mice for neuronal calcium studies (**B, C**), N = 4 mice for microglial calcium studies (**D--F**); the number of microdomains surveyed is provided in (**D**). \*p\<0.05, \*\*\*\*p\<0.0001.\
Figure 4---source data 1.Microglial calcium activity during kainate status epilepticus.](elife-56502-fig4){#fig4}

The prolonged seizure state induced by kainate, called status epilepticus, can also serve as a precipitating insult for the later acquisition of epilepsy ([@bib24]; [@bib34]; [@bib35]). In a second cohort of chronic window mice, we recorded baseline microglial calcium activity and then visually monitored status epilepticus severity after kainate administration ([Figure 5A](#fig5){ref-type="fig"}). Mice with more severe status epilepticus (≥8 generalized seizures) were longitudinally studied over a 14-day period for changes in microglial calcium signaling. For up to 7 days after kainate status epilepticus, layer I microglia displayed an altered morphology, marked by greater process ramification ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Over the same 7-day time course, a greater proportion of microglial somata and processes displayed calcium activity, with increased calcium signaling lasting up to 10 days ([Figure 5C--E](#fig5){ref-type="fig"}). During this period, microglial somata and processes could sustain high amplitude (\>2 fold ∆F/F) calcium transients for exceptionally long periods (1--4 min; see ∆F/F traces in [Figure 5C](#fig5){ref-type="fig"}). Calcium activity was also highly synchronized between the processes and soma, best exemplified by the appearance of large, spreading microglial calcium waves ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---Video 1](#fig5video1){ref-type="video"}). For these reasons, it is not surprising that the proportion of active microdomains and their signal areas are highly similar during this 14-day period ([Figure 5E](#fig5){ref-type="fig"}). Both somata and processes showed large increases in calcium activity before returning to near-baseline levels two weeks later ([Figure 5E](#fig5){ref-type="fig"}). Only after the excitotoxic insult represented by kainate status epilepticus do we observe consistent increases in microglial somatic calcium activity and the appearance of coordinated, whole-cell calcium transients. The appearance of both phenomena suggest microglial calcium activity can be fundamentally changed following excitotoxicity.

![Kainate administration leads to longitudinal modulation of microglial calcium signaling.\
(**A**) Timeline of experiment. (**B**) Representative images of microglia morphology at baseline and following kainate status epilepticus. See also: [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. (**C**) ∆F/F traces of microglial somatic and process calcium activity, using the threshold-based approach to detect microglial process territories. (**D**) Heat map of a microglial spreading calcium wave one day after kainate status epilepticus. Each row represents activity from a soma or one of 50 threshold-segmented process territories surveyed across this single field of view and animal. See also: [Figure 5---Video 1](#fig5video1){ref-type="video"}. Corresponding images of microglia across the whole field of view during the peak of wave activity, with a highlighted cell magnified. (**E**) Microdomains active and their signal areas (two-way ANOVA with Dunnett's post-hoc vs. baseline). (**F**) Representative changes in microglial process area (black line; 15 s avg. intensity images) correlated with ∆F/F calcium activity (purple line). Changes in process area were used to denote the start and end of retraction or extension. See also: [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}. (**G**) Based upon these criteria, extending processes were more likely to have associated calcium activity than processes undergoing retraction or remaining stable (horizontal bars, Fisher's exact test). Additionally, the calcium signals observed in extending processes were larger in magnitude (one-way ANOVA with Tukey's post-hoc test; the number of sampled regions fitting each criterion is provided in the bar; mean ± SEM). See also: [Figure 5---Video 2](#fig5video2){ref-type="video"}. (**H**) The percentage of processes exhibiting a calcium transient within a certain time window relative to the start of process extension or retraction. This analysis considers the closest temporally aligned calcium event preceding and/or following the start of extension/retraction (see methods for further details; survey of 55 extending processes and 39 retracting processes; Fisher's exact test). Scale bar: 50 µm (**D**). N = 5 GCaMP6s;Cx3Cr1^CreER-eYFP^ mice. Grouped data represent mean ± SEM; dashed lines represent individual animals (**E**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.\
Figure 5---source data 1.Longitudinal changes in microglial calcium activity following kainate status epilepticus.](elife-56502-fig5){#fig5}

In the days following kainate status epilepticus, microglial processes became exceptionally motile ([Figure 5F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), allowing us to study a number of motility events and their relationship with process calcium activity. One day after kainate status epilepticus, we find that 93% of microglial processes undergoing extension exhibit calcium activity, compared to 45% of stable processes and 38% of retracting processes ([Figure 5G](#fig5){ref-type="fig"}). Extending processes also exhibit calcium signaling nearly three-times the magnitude of stable or retracting processes ([Figure 5G](#fig5){ref-type="fig"} and [Figure 5---Video 2](#fig5video2){ref-type="video"}). When charting the temporal relationship between a calcium event and the beginning of extension or retraction ([Figure 5F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), we find that 51% of extending processes have a closely aligned calcium event (within 60 s), compared to 18% of retracting processes ([Figure 5H](#fig5){ref-type="fig"}). Our analysis suggests that after status epilepticus, microglial process extension is temporally correlated and strongly associated with their calcium activity.

DREADD-based modulation of excitatory neuronal activity is sufficient to induce microglial calcium signaling {#s2-4}
------------------------------------------------------------------------------------------------------------

Isoflurane- and kainate-based changes in neuronal activity represent two of the more extreme shifts in network function. We additionally employed chemogenetic approaches to achieve smaller, more direct alterations to network function. DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) utilize the expression of exogenous G-protein receptors to modulate cellular activity ([@bib26]). We used a Gi system (hM4D) targeted to local CaMKIIa neurons of the somatosensory cortex to decrease neuronal activity and a Gq system (hM3D) to increase neuronal activity ([Figure 6A](#fig6){ref-type="fig"}). In a first series of experiments, we tested multiple doses of the DREADD ligand, Clozapine N-oxide (CNO), with the goal of finding a dose that could produce modest (30--40%) and intermediate (60--70%) changes in excitatory neuronal calcium activity. We also examined the time of peak effect in both systems between 15 and 60 min after injection ([Figure 6A](#fig6){ref-type="fig"}, timeline). In the Gi system, a 2.5 mg/kg (i.p.) dose of CNO decreased CaMKIIa calcium signaling by 51 ± 4.2%, while a 5.0 mg/kg dose decreased signaling by 66 ± 3.5%. Due to the similar responses, a 1.25 mg/kg (i.p.) dose of CNO was also tested, resulting in a 31 ± 2.7% decrease in CaMKIIa calcium activity. In the Gi system, peak reductions in excitatory signaling were reached 30 min after injection and were sustained for at least 30 min thereafter ([Figure 6B,D and E](#fig6){ref-type="fig"}). In the Gq system, a 2.5 mg/kg (i.p.) dose of CNO increased excitatory neuronal calcium signaling by 42 ± 6.5%, while a 5.0 mg/kg dose increased signaling by 70 ± 8%. In the Gq system, there was a clear peak effect 30--45 min after injection ([Figure 6C--E](#fig6){ref-type="fig"}). In a control study, the highest dose of CNO used (5 mg/kg) did not alter neuronal calcium signaling in mice without DREADD transfection ([Figure 6E](#fig6){ref-type="fig"}). Based upon these tests, we adopted a 1.25 and 5.0 mg/kg dose of CNO in the Gi system, and a 2.5 and 5.0 mg/kg dose in the Gq system to impart modest or intermediate effects, respectively.

![DREADD-based modulation of excitatory neuronal activity is sufficient to induce microglial calcium signaling.\
(**A**) AAVs injected into the somatosensory cortex of WT mice in order to study DREADD-based changes in neuronal calcium activity (top). Experiment outline (bottom). (**B--C**) Representative ∆F/F traces of layer 2/3 CaMKIIa neuronal calcium activity at baseline and after CNO injection in the Gi (**B**) and Gq (**C**) systems. (**D**) Saline or CNO dose-dependent effects on neuronal calcium activity in the Gi and Gq systems over 15 min imaging periods (one-way ANOVA with Dunnett's post-hoc comparison to saline). (**E**) Summary of DREADD-based effects on neuronal calcium activity (at the time of peak effect: 30--45 min post injection; two-way ANOVA with Dunnett's post-hoc comparison to baseline). (**F**) Method to study DREADD-based changes in neuronal activity on microglial calcium signaling. mCherry expression served as a positive control for successful DREADD transfection. (**G--H**) Representative ∆F/F traces of microglial soma and process territory calcium activity at baseline and after CNO injection in the Gi (**G**) and Gq (**H**) systems. The threshold-based ROI approach was used to detect process regions. (**I**) Microglial process territory calcium activity in the Gi and Gq systems over 15 min imaging periods (one-way ANOVA with Dunnett's post-hoc vs. saline). (**J**) Summary of DREADD-based effects on microglial process territory calcium activity (at the time of peak effect: 45--60 min post injection; two-way ANOVA with Dunnett's post-hoc comparison to baseline). (**K**) The mean ± SEM calcium signal area is plotted for microglial process territories that remained stable, demonstrated new process outgrowth, or exhibited retraction 45--60 min after 5 mg/kg CNO injection in the Gi DREADD system (one-way ANOVA with Tukey's post-hoc test; process sample size given in the bar). The percentage of processes exhibiting calcium activity by motility/structural characteristic is displayed in the horizontal bars (Fisher's exact test). (**L**) The same analyses as performed in (**K**) for the Gq DREADD system (see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for more detail). Scale bars: 50 µm (**B**, **C**, and **F**), 10 µm (**G-H**). (**A-E**) N = 8 WT mice, N = 4/8 receiving AAV-CaMKIIa-hM4D(Gi) and N = 4/8 receiving AAV-CaMKIIa-hM3D(Gq). (**F-J**) N = 6 GCaMP6s;Cx3Cr1^CreER-eYFP^ mice, half receiving Gq or Gi DREADD. Grouped data represent mean ± SEM; dots represent individual animals (**E, J**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. See also: [Figure 6---Video 1](#fig6video1){ref-type="video"}.\
Figure 6---source data 1.Microglial calcium activity during Gi and Gq DREADD activation in CaMKIIa neurons.](elife-56502-fig6){#fig6}

To this end, GCaMP6s;Cx3Cr1^CreER-eYFP^ mice were transfected with DREADD virus and microglial calcium activity was studied in the area of peak neuronal expression (mCherry tag; [Figure 6F](#fig6){ref-type="fig"}). In the Gi system, CNO-dependent decreases in CaMKIIa neuronal activity resulted in gradual increases in microglial process calcium activity, peaking 45--60 min after injection ([Figure 6G,I , J](#fig6){ref-type="fig"}, and [Figure 6---Video 1](#fig6video1){ref-type="video"}). Notably, there were clear dose-dependent differences in the extent of microglial process calcium activity after CNO injection ([Figure 6I and J](#fig6){ref-type="fig"}), with a 64 ± 11% increase observed at the lower dose (1.25 mg/kg) and a 133 ± 26% increase observed at the higher dose (5.0 mg/kg). In the Gq system, microglial process calcium activity displayed highly similar trends to the Gi system, despite the fact that these approaches resulted in opposing shifts to neuronal activity (hypoactivity in the Gi system and hyperactivity in the Gq system). At the lower dose in the Gq system, 2.5 mg/kg CNO administration resulted in a 68 ± 31% increase in microglial process calcium activity, while the higher dose (5.0 mg/kg) resulted in a 128 ± 13% increase in process calcium activity ([Figure 6H--J](#fig6){ref-type="fig"}, and [Figure 6---Video 1](#fig6video1){ref-type="video"}). In both the Gi and Gq systems, peak microglial calcium responses occurred 45--60 min after CNO administration, suggesting an approximate 15 min latency relative to peak neuronal changes ([Figure 6D and I](#fig6){ref-type="fig"}). Additionally, both Gq- and Gi-based alterations to excitatory neuronal activity did not result in observable changes to microglial somatic calcium signaling (data not shown). Similar to isoflurane and kainate experiments, microglial process extension/outgrowth was the predominant motility behavior observed following Gi- or Gq-DREADD activation in neurons ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Extension was the motility behavior most closely associated with calcium activity and large signal magnitude ([Figure 6K,L](#fig6){ref-type="fig"}, and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Overall, we observe that a near-linear range of neuronal activity shifts ([Figure 6E](#fig6){ref-type="fig"}) results in a U-shaped curve of microglial process calcium activity ([Figure 6J](#fig6){ref-type="fig"}), with the greatest shifts in neuronal activity producing the largest microglial process calcium signaling ([Figure 7](#fig7){ref-type="fig"}).

![Summary of findings and observed relationship between neuronal activity and microglial calcium signaling.\
(**A**) During 'baseline' levels of neuronal activity in the awake mouse (middle panel), microglia demonstrate the lowest level of process calcium activity. However, shifts towards neuronal hypoactivity (isoflurane or Gi DREADD activation, top panel) or hyperactivity (kainate or Gq DREADD activation, bottom panel), result in microglial process extension and increased process calcium signaling after a multi-minute latency. (**B**) A near-linear range of neuronal activity (recorded as cortical layer II/III somatic calcium activity; bottom) results in a U-shaped curve of microglial process calcium increases (top panel). These data represent the average signal areas recorded across experiments.](elife-56502-fig7){#fig7}

Discussion {#s3}
==========

Herein, we describe a series of observations regarding microglial calcium signaling in response to shifts in neuronal activity. In general, microglia are considered to have the lowest levels of spontaneous calcium activity in 'resting' or 'baseline' states from reports in anesthetized mice ([@bib3]; [@bib5]; [@bib23]). We observe that microglial calcium activity is similarly low in awake, chronic window mice ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). However, pharmacological alterations in neuronal activity can trigger microglial process calcium signaling without impacting somatic calcium signaling ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}). In general, microglial process calcium signaling follows a U-shaped curve, with greater shifts in neuronal activity (both hypoactive or hyperactive) resulting in stronger process calcium signaling ([Figure 7](#fig7){ref-type="fig"}). Additionally, both shifts in network activity were associated with microglial process extension/outgrowth. Extending processes consistently demonstrated the greatest calcium activity. Our work initially suggests that microglial calcium signaling may be an important component in how microglia address brain state changes.

Spontaneous microglial calcium activity and the utility of different GCaMP variants and preparations {#s3-1}
----------------------------------------------------------------------------------------------------

Microglial have low spontaneous calcium activity in the anesthetized animal ([@bib3]; [@bib5]; [@bib23]), relative to reports of calcium activity in neurons and astrocytes. We initially wanted to determine if low spontaneous calcium activity in earlier reports was a product of the anesthesia used during imaging. Even in the awake animal, microglia do indeed display very infrequent spontaneous process and soma calcium activity ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Previous studies also arrive on a key concept that injury, damage, and inflammation all produce increased or altered microglial calcium signaling ([@bib3]; [@bib2]; [@bib5]; [@bib23]). As resident CNS immune cells, microglia have a strong ability to sense inflammation and even low-level injury, which can occur during a craniotomy. By some reports, microglia can maintain a more reactive phenotype for multiple weeks after craniotomy ([@bib39]). For this reason, it was important that we compare microglial calcium signaling in an acute and chronic window preparation ([Figure 2](#fig2){ref-type="fig"}). We found multiple lines of evidence that microglial process calcium signaling, but not somatic signaling, may be artificially inflated in the acute window preparation. In acute window preparations, a higher proportion of processes exhibited calcium signaling, and a subset of processes displayed calcium signals that were orders of magnitude above the average. In chronic window animals, both of these phenomena were attenuated. However, we could still evoke larger or widespread process calcium activity in chronic window animals, but only after introducing local or systemic changes in circuit activity (i.e. kainate). These observations suggest that chronic window preparations may better reflect the occurrence and magnitude of true spontaneous microglial calcium activity. The stability of spontaneous calcium activity in this preparation over multiple days also suggests that it is ideal for longitudinal studies.

One of the more unique observations made in our initial studies is the low-level, sometimes widespread fluorescent signature reported by the Lck-GCaMP6f animal ([Figure 1E](#fig1){ref-type="fig"}). We initially investigated calcium signaling using the Lck-GCaMP6f animal, because tethering GCaMP to the cell membrane could reveal key calcium signals in fine process structures, as demonstrated for astrocytes ([@bib27]). We hypothesize that the coordinated, low-level signals detected by the Lck-GCaMP6f mouse could reflect neuronal activity changes sensed by surrounding microglial processes. In future studies, we will use bipolar EEG recording inside of the window to determine if the widespread, low-level fluorescent signature reported by Lck-GCaMP6f indicator is temporally well-aligned with increased cortical activity. If so, this approach could provide the first evidence that microglia can respond to neuronal activity in real time. Prior reports have demonstrated real-time calcium responses only in the presence of pathology or injury ([@bib5]).

An interesting question is whether the different GCaMP variants may also be able to report different mechanisms for calcium elevations. Given its cytosolic localization, GCaMP6s may be better suited to detect calcium release from the endoplasmic reticulum, which is canonically attributed to Gq-coupled GPCR signaling. On the other hand, the membrane localization of Lck-GCaMP6f may be able to detect calcium entry through membrane channels. Microglia express both ionotropic and metabotropic receptors for calcium elevations, particularly in the P2X (e.g. P2X7, [@bib7]) and P2Y (e.g. P2Y6, [@bib15]) family. Pharmacology experiments in vivo suggest that both routes of calcium entry are potentially viable in microglia ([@bib5]), but cytosolic calcium levels may be more important in damage responses ([@bib5]; [@bib23]). On the other hand, our previous work also suggests that extracellular calcium inhibits microglial process convergence, a key response to neuronal hyperactivity ([@bib9]). Future studies will investigate the potential signaling mechanism(s) underlying microglial calcium elevations in response to neuronal hyperactivity and hypoactivity.

The relationship between neuronal activity changes, process extension, and process calcium signaling {#s3-2}
----------------------------------------------------------------------------------------------------

Both approaches to increase or decrease neuronal activity resulted in elevated microglial calcium activity after a 6 to 15 min latency. The nature of the latency between neuronal changes and microglial calcium signaling does not suggest that microglia have a real-time response to neuronal activity in these instances. Instead, microglia appear to mobilize calcium signaling some minutes later. Our results suggest that microglial calcium signaling after neuronal activity changes is correlated with process motility, and extension in particular. This could reasonably explain the observed latency between neuronal activity and microglial calcium signaling. Our previous report suggests that isoflurane anesthesia applied to the awake mouse engages maximal process movement after a delay of up to 10 min ([@bib18]), and our process area analysis in the current study replicates these findings ([Figure 3H](#fig3){ref-type="fig"}). On a similar timescale to process extension/outgrowth, microglia begin to show elevated process calcium signaling (6 min delay). We posit that the calcium associated with extending processes contributes to the majority of the overall calcium signaling observed. Similarly, we observe elevated microglial process calcium activity after Gq or Gi DREADD activation in CaMKIIa neurons. In these studies, peak microglial calcium activity was delayed by approximately 15 min from the timing of peak of neuronal activity. This longer delay may be attributable to the more gradual alterations in neuronal activity produced by DREADD-based approaches or the lesser overall magnitude of changes observed (30% to 70% change in neuronal calcium activity relative to an immediate 90% decrease under isoflurane). In either case, the timing of microglial process calcium activity follows the time course of motility changes, with extending processes contributing the most to overall calcium increases. This time scale is also on par with other microglial process motility responses, such as laser burn or local ATP, which require 10--20 min for processes to fully extend ([@bib4]; [@bib38]).

The relationship between motility and calcium signaling in microglia, first observed in culture ([@bib17]; [@bib21]), is complex. Extending processes are not categorically associated with calcium activity in the present study (67--93% of extending processes had calcium activity across experiments). The temporal relationship between extension and calcium activity is also not universal, with approximately 50% of extending processes having a closely timed calcium event when studied after kainate status epilepticus ([Figure 5H](#fig5){ref-type="fig"}). As a ubiquitous secondary messenger, calcium signaling is not expected to perfectly align with any one cellular function, such as motility. Our results suggest that calcium may be an important contributor to extension. Previous studies in vivo have shown that chelating calcium in microglia can reduce process velocity, but not abolish movement entirely ([@bib23]). Thus, calcium could be a co-regulator of motility under certain conditions, potentially modulating the P2Y12/Gi-based cAMP pathway or PI3 kinase signaling canonically implicated in process movement ([@bib13]; [@bib38]).

Another key future consideration is whether microglial calcium signaling occurs specifically when neuronal activity shifts away from baseline specifically, or shifts in any manner (such as a shift from hypoactive back to baseline). We would hypothesize that shifts back to baseline may not be accompanied by microglial calcium activity, based upon the types of motility associated with these shifts. Specifically, we posit that process retraction would be most prominently observed during shifts back to baseline, and retracting processes rarely appear to mobilize calcium activity. These experiments will be ideal for testing predictions made from our early observations about the relationship between different motility behaviors and calcium signaling.

The importance of microdomains in understanding glial calcium activity {#s3-3}
----------------------------------------------------------------------

Our findings clarify the role of neuronal activity on microglial calcium signaling. Previous studies using the GABA antagonist bicuculline to increase neuronal firing have come to different conclusions. In a first study, bicuculline did not alter microglial calcium activity ([@bib5]). However, this earlier study investigated bicuculline effects largely by imaging microglial somatic calcium activity reported through a calcium indicator dye. Our work suggests that it is unlikely that acute changes in neuronal activity, even under seizure conditions, will dramatically impact microglial somatic calcium activity. In a more recent study using the calcium indicator GCaMP5G, microglia exhibited strong calcium wave activity when bicuculline was applied ([@bib23]). Notably though, changes in neuronal activity were evoked in an inflammatory context, specifically occurring 12--24 hr after LPS application, which suggests a synergy between inflammation and excitation on microglial calcium activity. We hypothesize that this observation is informative for interpreting our longitudinal studies following kainate status epilepticus. The period following a brain insult like status epilepticus alters neuronal network synchronization, but it can also provoke inflammation ([@bib1]; [@bib14]; [@bib32]; [@bib36]). Under these inflammatory and epileptogenic conditions, we similarly observe wave-like calcium activity in approximately 10% of imaging sessions, similar to the frequency described with bicuculline and LPS ([@bib23]). Notably, only under these long-term, pro-inflammatory conditions do we observe clear changes in microglial somatic calcium activity. The profoundly altered calcium signaling properties of microglia following status epilepticus, including whole-cell calcium transients, suggests that calcium may serve as a key secondary messenger system in microglia during disease development.

An important consideration in our work is the potential impact of the low-level eYFP signal. This signal was consistently detected alongside dynamic changes in GCaMP6 fluorescence, contributing to a higher baseline (F~0~) in ∆F/F~0~ calculations. For these reasons, our work could underestimate the amount of calcium activity in microglia. Additionally, the eYFP signal could mask small, but biologically important calcium signals, like those reported in astrocytes ([@bib27]). This could be most prominent in the soma, which exhibits a stronger eYFP signal. However, our results do not suggest such a caveat is likely to influence our major findings, as detected soma events were large in amplitude, prolonged, and exceedingly rare in the absence of pathology. In addition, these conclusions are very similar to other in vivo studies ([@bib5]; [@bib23]), which recorded somatic microglial calcium activity in the absence of an eYFP signal. Of interest, our microdomain analysis suggest a similar concept in how both astrocytes and microglia utilize calcium activity. Astrocytes are known to exhibit calcium signaling most often in their fine processes, with somatic elevations being relatively less common ([@bib31]). Thus, in both cases, it appears glial cells exhibit more calcium activity in their smaller process domains---the regions most likely to interact with synapses, other glia, or vasculature ([@bib40]).

The mechanisms regulating microglial calcium signaling have not been clearly identified. ATP/ADP is the most definitive agonist of microglial calcium signaling to date, and purinergic receptors (ionotropic P2X and metabotropic P2Y family) have been clearly implicated in transducing microglial calcium signaling ([@bib5]; [@bib11]; [@bib23]). While kainate and the Gq DREADD system could reasonably increase the release of purinergic signaling molecules ([@bib6]), evoking both process outgrowth (canonically P2Y12-driven, [@bib8]; [@bib13]; [@bib30]) and process calcium activity (potentially P2Y6-driven, [@bib15]), it would be illogical for Gi DREADD and isoflurane to increase purinergic signaling. Recent studies suggest that depressing neuronal activity in the awake mouse prevents noradrenergic signaling to microglial β2 receptors ([@bib18]; [@bib29]). During awake imaging, β2 receptor activation in microglia restrains process surveillance, motility, and extension, keeping microglia in a relatively arrested state. The absence of this signaling axis when neuronal activity is reduced allows for extension, as we observed here in isoflurane and Gi DREADD studies. What is unclear, however, is whether β2 receptor disinhibition also contributes to microglial calcium signaling during neuronal hypoactivity. In future, it will be critical to determine the mechanisms that govern microglial calcium responses to bidirectional shifts in neuronal activity. It is indeed possible that microglia indirectly respond to neuronal activity shifts, potentially through other cell types, like astrocytes, or even associated vascular changes; however, DREADD-based experiments do suggest that direct neuronal activity shifts are upstream of microglial calcium elevations. Overall, we demonstrate that microglia display increases in process calcium signaling following bidirectional shifts in neuronal activity. Our work leaves open the possibility that microglial calcium signaling represents an important component in how microglia address brain state changes.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                                Designation                          Source or\        Identifiers                                                                                 Additional\
  (species) or\                                                                                     reference                                                                                                     information
  resource                                                                                                                                                                                                        
  ------------------------------------------------------------ ------------------------------------ ----------------- ------------------------------------------------------------------------------------------- --------------------------------
  Strain, strain background (*M. musculus*; male and female)   C57BL/6J                             Jackson labs      \#016962                                                                                    

  Strain, strain background (*M. musculus*; male and female)   CX3CR1^CreER-IRES-eYFP^              Jackson labs      \#021160                                                                                    

  Strain, strain background (*M. musculus*; male and female)   GCaMP6s (cytosolic)                  Jackson labs      \#024106                                                                                    

  Strain, strain background (*M. musculus*; male and female)   Lck-GCaMP6f                          Jackson labs      \#029626                                                                                    

  Transfected construct (*M. musculus*)                        pENN.AAV.CaMKII.GCaMP6f.WPRE.SV40    Addgene           Cat \#: 105537-AAV9; RRID:[Addgene_100834](https://scicrunch.org/resolver/Addgene_100834)   

  Transfected construct (*M. musculus*)                        pAAV.CaMKIIa.hM3D(Gq)-mCherry        Addgene           Cat \#: 50476-AAV5; RRID:[Addgene_50476](https://scicrunch.org/resolver/Addgene_50476)      

  Transfected construct (*M. musculus*)                        pAAV.CaMKIIa.hM4D(Gi)-mCherry        Addgene           Cat \#: 50477-AAV5; RRID:[Addgene_50477](https://scicrunch.org/resolver/Addgene_50477)      

  Chemical compound, drug                                      Clozapine N-Oxide                    Cayman            Cat \#: 16882                                                                               

  Chemical compound, drug                                      Isoflurane                           Terrell           Cat \#: 66794-019-10                                                                        

  Chemical compound, drug                                      Kainic acid                          Tocris            Cat \#: 0222                                                                                

  Chemical compound, drug                                      Tamoxifen chow                       Envigo            Cat \#: TD.130856                                                                           

  Software, algorithm                                          Excel                                Microsoft                                                                                                     

  Software, algorithm                                          ImageJ                               NIH                                                                                                           Java 1.8.0_172

  Software, algorithm                                          Prism                                GraphPad                                                                                                      Version 8

  Other                                                        5.2 mm Headplate                     Neurotar          Model 2                                                                                     

  Other                                                        Closed-loop temperature controller   Physitemp         TCAT-2DF                                                                                    Used during isoflurane imaging

  Other                                                        VivoScope Galvo\                     Scientifica                                                                                                   
                                                               Multiphoton                                                                                                                                        

  Other                                                        Mai-Tai DeepSee                      Spectra-Physics   MAI TAI HP DS                                                                               2-P laser

  Other                                                        Mobile HomeCage                      Neurotar          Cat \#: NTR000289-01                                                                        Air table for in vivo imaging

  Other                                                        UMP3 Ultra Micro Pump                WPI               Cat \#: UMP3-4                                                                              Used in AAV delivery
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

GCaMP6s (Rosa26-CAG-LSL-GCaMP6s; 024106), Lck-GCaMP6f (Rosa26-CAG-LSL-Lck-GCaMP6f; 029626), and CX3CR1^CreER-eYFP^ (021160) knock-in mouse lines can be obtained from the Jackson Laboratory. Neuronal calcium activity was studied in C57BL/6J WT mice using AAV injections. Both male and female offspring were used across all studies at an age ranging from 3 to 5 months. Mice were group housed in an AAALAC-approved facility in climate-controlled rooms with a 12 hr light/dark cycle (lights on at 6am) and had free access to food and water. All experimental procedures were approved by the Mayo Clinic's Institutional Animal Care and Use Committee (IACUC).

Administration of tamoxifen in chow {#s4-2}
-----------------------------------

In CreER lines, tamoxifen was administered through chow to activate GCaMP expression in microglia. Mice were weaned at P21 and then provided tamoxifen in chow for a two-week period (250 mg tamoxifen per 1 kg of chow; Envigo). Notably, chronic window studies occurred no sooner than 4 weeks after tamoxifen administration ended, which is sufficient to label microglia but not peripheral CX3CR1 cell types due to differences in their turnover rates ([@bib22]).

Stereotaxic delivery of AAV {#s4-3}
---------------------------

Under isoflurane anesthesia (4% induction, 1.5--2.5% maintenance), AAVs were injected into the somatosensory cortex (AP: −4.5, ML: +2.0) using a glass pipette and micropump (World Precision Instruments). AAVs were targeted to both layer V neurons (DV: −0.5) and layer II/III neurons (DV: −0.2). A 250 nL volume was dispensed at each level at a 40 nL/min rate followed by a 10-min rest period for diffusion. pENN.AAV9.CaMKII.GCaMP6s.WPRE.SV40, AAV5.CaMKIIa.hM3D(Gq)-mCherry, and AAV5.CaMKIIa.hM4D(Gi)-mCherry were either injected alone (1:1 dilution in PBS) or in conjunction (1:1 ratio of DREADD and GCaMP virus). All viruses were used at a titer of 10^12^ GC/mL and acquired from Addgene.

Cranial window surgery {#s4-4}
----------------------

Cranial windows were implanted following standard techniques. Under isoflurane anesthesia (4% induction, 1.5--2.5% maintenance), a circular craniotomy (\<3 mm diameter) was made over somatosensory cortex (AP: −4.5, ML: +2.0) using a high-speed dental drill. A circular glass coverslip (3 mm diameter, Warner) was secured over the craniotomy using Loctite 401 at the lateral edges. A four-point headbar (NeuroTar) was secured over the window using dental cement. A mild NSAID solution (0.2 mg/mL Ibuprofen) was provided in the home cage for 72 hr following surgery. In mice undergoing AAV injections, windows were implanted over the injection site after a 3-week recovery period.

Two-photon imaging: acute and chronic imaging parameters {#s4-5}
--------------------------------------------------------

Imaging in the awake animal was performed using a Scientifica multiphoton microscope equipped with galvanometer scanning mirrors. To image GCaMP fluorescence, a Mai-Tai DeepSee laser was tuned to 920 nm and kept below 50 mW output for layer I imaging or 55 mW output for layer II/III imaging, as measured directly under the objective. Both the eYFP and GCaMP6s signals were passed through a 520/15 filter (Chroma). Imaging occurred at a 1 Hz frame rate at 512 × 512 pixel resolution using a 16x water-immersion objective (NA: 0.8, Nikon). Microglial calcium was imaged at a consistent zoom factor (300 × 300 µm area), while neuronal calcium was sampled from a larger area (450 × 450 µm).

Two-photon imaging: training and baseline imaging ([Figure 2](#fig2){ref-type="fig"}) {#s4-6}
-------------------------------------------------------------------------------------

Mice were trained to move on an air-lifted platform (NeuroTar) while head-fixed under a 2P objective. Training occurred for 30 min/day for the first 3 days following surgery and once per week thereafter. On the first day following surgery, a subset of mice was imaged to determine baseline microglial calcium activity in the acute window. Chronic imaging occurred no sooner than 4 weeks after surgery in mice with a clear window. Across all studies, mice were allowed 10 min to acclimate after being placed in the head restraint before imaging began. For studies of spontaneous calcium activity in awake acute and chronic window animals, a 15-min video was acquired 55--75 µm below the dura (layer I) and 150--170 µm below the dura (layer II/III).

Two-photon imaging: isoflurane studies ([Figure 3](#fig3){ref-type="fig"}) {#s4-7}
--------------------------------------------------------------------------

A cohort of chronic window GCaMP6s;Cx3Cr1^CreER^ mice and AAV9.CaMKII.GCaMP6s WT mice was first imaged under awake, baseline conditions (10 min; 55--75 µm depth for microglia, 150--170 µm depth for neurons). A nose cone was then secured to the head-restraint system and the mouse was induced with isoflurane on the platform (4%, up to 60 s). Isoflurane was maintained at 1.5--2% for the duration of imaging, acquired as three 10 min blocks. Under isoflurane, body temperature was maintained at 37°C (Physitemp).

Two-photon imaging: kainate studies ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) {#s4-8}
-------------------------------------------------------------------------------------------------------

Two separate cohorts of GCaMP6s;Cx3Cr1^CreER^ mice were used to study either the acute effects of kainate during status epilepticus ([Figure 4](#fig4){ref-type="fig"}) or the longitudinal effects of KA-SE over a 14 d period ([Figure 5](#fig5){ref-type="fig"}). To study the acute effects of kainate status epilepticus, a cohort of chronic window mice were imaged at baseline (15 min, 60--75 µm depth) then removed from the stage and injected with 19 mg/kg kainate (i.p.). Mice were then visually monitored for a generalized seizure (defined by Racine stage 3--5 criteria; [@bib25]). The same region was then imaged for 30 min following the first generalized seizure, which began 45--75 min after injection. To study the longitudinal effects of status epilepticus in a separate cohort, a 15 min baseline recording was taken from two separate regions of the cranial window (55--80 µm depth). Kainate was then administered (19 mg/kg, i.p.) and seizures were visually monitored. After 1 hr, booster injections (7.5 mg/kg, i.p.) were administered every 30 min to animals not displaying a generalized seizure until such time as mice displayed at least eight generalized seizures. Chronic window mice meeting these inclusion criteria were then re-imaged in the same two locations 1, 2, 3, 7, 10, and 14 days after status epilepticus.

Two-photon imaging: chemogenetic studies ([Figure 6](#fig6){ref-type="fig"}) {#s4-9}
----------------------------------------------------------------------------

To validate the DREADD approach and determine CNO dose responses, we used WT C57BL/6J mice co-injected with AAV9.CaMKII.GCaMP6s and either AAV5.CaMKIIa.Gi-mCherry, or AAV5.CaMKIIa.Gq-mCherry. A cohort of mice injected with AAV9.CaMKII.GCaMP6s alone was employed for a CNO control study. To study the effects of CaMKIIa-DREADD effects on microglial calcium, we injected the Gq or Gi virus into GCaMP6s;Cx3Cr1^CreER^ mice. All experiments were performed in chronic window animals (minimum of 4 weeks after window surgery and 7 weeks after virus injection). Somatic changes in neuronal calcium were studied in layer II/III (150--170 µm), while microglia were studied in layer I (55--75 µm depth). As a positive control for microglial studies, imaging was only performed in a region with high mCherry expression (visualized with a 740 nm excitation wavelength), and this region remained consistent across all trials. A trial consisted of a 15 min acclimation period to head restraint, 15 min baseline imaging session, removal and injection (saline or 1.25, 2.5, or 5.0 mg/kg CNO, i.p.), 15 min re-acclimation period under head restraint, then three 15 min post-injection imaging blocks. Post-injection changes in calcium activity were compared to the daily baseline period. CNO trials were separated by at least 48 hr, with lower doses administered first.

Calcium image processing and ROI selection {#s4-10}
------------------------------------------

T-series of neuronal and microglial calcium activity were motion corrected in ImageJ using the template matching plugin with subpixel registration. An average intensity image of morphology was then generated for ROI selection. For neuronal somata, ROIs were manually drawn with the circle tool for all neuronal somata detected in layer II/III, which appeared as a light ring with a dark circular nucleus. For microglia, two approaches to ROI selection were used. In both approaches, an average intensity projection was created from the T-series. Notably, the low-intensity but constitutive eYFP signal of microglia is preferentially captured in the average intensity projection, providing an image of cell morphology that is not strongly influenced by overall calcium activity. In the first approach, used to characterize microdomain activity in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, somata and processes were manually segmented using the 'freeform' tool (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for examples). Based upon their size and intensity, somata could be identified without ambiguity. Process segmentation followed three main rules: 1) the process had to be associated with a soma in the field of view, 2) all visible primary branches were segmented, and 3) any secondary branches emanating from a primary branch was segmented if greater than 15 pixels in length (\~10 µm). This approach is referred to as 'manual segmentation' in the text and the resulting process ROIs are termed 'processes' in figures. In the second approach, semi-automated microglial process detection was utilized, as in [Figures 3](#fig3){ref-type="fig"}--[6](#fig6){ref-type="fig"}, when an intervention was introduced that could result in a hypothesized change in calcium activity. In this approach, termed 'threshold-based' ROI selection, the following steps occurred: 1) the unambiguous microglial somata were manually segmented by the freeform tool; 2) after acquiring their intensity values for ∆F/F calculations, these brighter somata were masked in the average intensity image to better threshold processes; 3) process territories were then identified in a semi-automated fashion using the threshold tool at a user-defined threshold level; 4) any process area larger than 50 pixels was included in the ROI manager; 5) these ROIs were then used to obtain intensity values. The threshold-based ROIs generated through these methods are termed 'process territories' as they often represent a primary process with multiple secondary and tertiary branches.

Calcium activity analysis {#s4-11}
-------------------------

Using the ROIs generated through the above methods, the multi-measure tool was used to obtain mean intensity values, which were converted into ∆F/F values using Excel. To determine the baseline fluorescence, we created a 100 s moving window average and then found the lower 25^th^ quartile value across all frames. In certain cases of high activity, such as seizures during status epilepticus or spreading microglial calcium waves, the baseline was determined by finding the lower 25^th^ quartile value in a user-selected, 200-frame period of non-seizure or non-wave activity. A calcium transient was considered to occur at a ∆F/F threshold over three times greater than the standard deviation of the baseline. The signal area represents the sum of any ∆F/F value above this threshold across all frames. A soma or process was considered active if it had a signal area of ≥5 ∆F/F∙s.

Process area and Sholl analyses {#s4-12}
-------------------------------

In experiments where motility changes were evaluated in real time (i.e. during the single-day experiments), we determined changes in overall process area ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Using average intensity projections of the eYFP signal (full 600 or 900 frames), microglial somata were masked and a uniform threshold was applied to determine the process area. In longitudinal experiments ([Figures 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}), morphological complexity was determined using the Sholl analysis plugin of ImageJ ([@bib12]).

Motility analysis and assessment of extension or retraction {#s4-13}
-----------------------------------------------------------

To determine process motility behavior, an average intensity image was generated from the first and last 100 frames of the T-series. From these images, a two-color overlay image was created (red: first; green: last). This image was used to initially highlight processes that underwent retraction (red color), extension (green color), or remained stable (red/green merge; see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for example). ROIs were manually created around each process then multiple steps were taken before final inclusion. First, all processes selected needed to be a minimum size for inclusion (\>9 µm^2^). Second, each process was visually inspected in the T-series for extension, retraction, or stability. Finally, processes needed to display at least a 50% area enlargement to be considered an extension (e.g. 10 µm^2^ to 15 µm^2^) or 50% area decrease to be considered a retraction (e.g. 10 µm^2^ to 5 µm^2^). Stable processes had less than a 50% change in area in either direction. After confirmation, these ROIs were also used to generate ∆F/F calcium traces to determine signal area and associated calcium activity based on each motility characteristic ([Figures 3I](#fig3){ref-type="fig"}, [5G](#fig5){ref-type="fig"}, [6K and L](#fig6){ref-type="fig"}). A process was considered to be associated with calcium activity if it had a signal area of \>5 ∆F/F∙s.

To determine temporal correlations between process extension/retraction and calcium events ([Figure 5H](#fig5){ref-type="fig"}), processes were selected as previously described using a manual ROI. We determined the start and end time of an extension/retraction event by using the threshold tool to create a frame-by-frame assessment of process area. The start of extension was defined as the first frame in a series of frames where process area became sequentially larger, while the end of extension was defined by a plateau in process area. The start of retraction was defined as the first frame in a series in which the process area began to reduce, while the end of retraction was defined by a plateau at a minimum value. We determined the temporal relationship between this extension/retraction start time and calcium events by determining the closest calcium event before and after the start time (if present, see [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} for examples). A calcium event needed to have a peak ∆F/F value of 0.5 to be considered, and only the nearest event before or after was considered. The latency between the peak of these calcium events relative to the start of extension/retraction was calculated for all extending/retracting processes in the [Figure 5](#fig5){ref-type="fig"} analysis and then binned by processes with an \<30 s,\<60 s, or \<120 s latency between calcium event and extension/retraction start.

General statistical analysis {#s4-14}
----------------------------

A pilot study was first performed in acute window animals (N = 5) to determine the effect size and variability that isoflurane and acute kainate exposure had on microglial calcium activity. Based upon variability derived from these preliminary data, a power analysis was performed and an appropriately sized cohort was determined at a 0.05 alpha and 0.70 power level.

Two major effects were biologically replicated across two cohorts. We first observed the effects of kainate and isoflurane on microglial calcium activity in a pilot cohort (N = 5) using acute window animals. We then studied these effects in a separate cohort using chronic window animals (chronic window findings are reported in the present study after [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). The effects of kainate and isoflurane were consistent in both cohorts and contexts. In addition, DREADD-based changes in both neuronal calcium activity and microglial calcium activity were technically replicated in the same respective cohorts after a 1-week delay. These replicates showed similar trends. Findings from the initial test are reported in the present study (not pooled or averaged). No outliers were removed from the data. The only grounds for animal study exclusion were based upon technical guidelines: two acute window animals were excluded due to post-operative cranial bleeding; approximately 30% of cranial window animals did not develop a sufficiently clear chronic window for adequate imaging and were excluded; two GCaMP6s;Cx3Cr1^CreER^ mice in DREADD studies (one transfected with Gq virus and one transfected with Gi virus) were excluded due to a rare chronic window bleed or the loss of a headcap, respectively.

Prism (GraphPad, version 8) was used for group analyses. In most experiments, statistical significance was determined using a one- or two-way ANOVA design with Dunnett post-hoc comparison to the values obtained in the baseline period. Differences in the proportion of active microdomains were assessed using a Fisher's exact test. All data are expressed as the mean ± SEM. Statistical details are provided in the figures and figure legend.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Microglial calcium signaling is attuned to neuronal activity\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \'in revision at *eLife*\'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

This interesting and innovative study used in vivo two photon imaging to assess microglial calcium dynamics in the upper layers of the cerebral cortex in awake mice. The studies used a range of pharmacological and genetic methods to induce widespread changes in neuronal activity and correlated these to microglial calcium levels, process dynamics and cell size. The general conclusions are important -- that microglia exhibit calcium dynamics that change with a substantial delay after altering neuronal activity, and that both increasing and decreasing neuronal activity leads to an increase in calcium and process extension.

Essential revisions:

1\) The authors used CX3CR1-CreER-ires-EYFP mice crossed with cre-dependent GCaMP6s and lck-GCaMP6f calcium indicators, and thus performed simultaneous imaging of EGFP and EYFP. Apparently, there was no attempt to split these signals -- due to their spectral overlap, it would be near impossible. As a result, the fluorescence changes reflect a combined GCaMP/EYFP signal. This needs to be clearly stated at the outset. As a result, the GCaMP signal to noise is reduced, so many smaller GCaMP fluctuations may have been missed. In the CX3CR1-CreER-ires-EYFP mice, the EYFP signal tends to be strongest in microglial somas -- will this then preferentially impact the ability to detect subtle changes in GFP signal within microglial somas? This issue should be discussed. If the authors have data from animals expressing GCaMP only, it would be helpful to include some of these data for comparison. A second caveat with this approach is that all fluorescence fluctuations are interpreted as changes in intracellular calcium. Given the small size of these processes and their dynamic nature, there is concern that movements could also contribute to the fluctuations observed. This issue also needs to be discussed. Large scale coordination of events such as that shown in Figure 1E (Eii) raise concerns about such potential artefacts.

2\) It is surprising that the authors did not use automated detection algorithms to identify and quantify microglia calcium transients and define microglial movements. A number of such programs have been developed and are readily available. The method of ROI categorization needs to be described more thoroughly and higher magnification images shown to validate the approach. They should show an example image that indicates a typical soma ROI and typical process ROIs with corresponding ΔF/F traces for those ROIs. (Figure 2C shows one cell with arrows but doesn\'t show the actual ROIs with some kind of outline). Without this information, there is confusion about what the ΔF/F traces represent. In Figures 1 and 2 -- are these soma and individual process ROIs from a single representative cell or multiple process ROIs from different cells across one field of view? In Figures 3 and 4 where \"process territory\" ROIs are used -- do the ΔF/F traces represent calcium signals in microglial processes in the entire field of view from different animals? Or process territories from different, individual microglial cells? What is the justification for examining individual process ROIs in Figures 1 and 2 but whole process territory ROIs in Figures 3 and 4? In Figures 5 and 6 the ΔF/F traces are labeled with \"Processes\" so it\'s unclear if individual ROIs on distinct regions of processes were used as in Figures 1 and 2 or if process territories were used as in Figures 3 and 4.

3\) In trying to address the question about what are the basic patterns of calcium activity in microglial cells, the authors miss an opportunity to provide additional, useful information using the images they have already acquired. Are the cells that show soma calcium elevations the same group of cells that show process elevations? Or can you sometimes see cells that have only soma calcium elevations or only process calcium elevations? Of the cells that do show calcium elevations, are they scattered throughout the field of view or do they tend to be spatially clustered close to one another? What about these same questions following isoflurane, kainate, or DREADD manipulations? Also -- if the mice are being imaged while on the NeuroTar air-lifted platform as described in the Materials and methods, can the authors comment about any relationship between microglial calcium elevations and ambulation or grooming?

4\) One of the most interesting aspects of the work relates to linking process dynamics to changes in intracellular calcium. However, this phenomenon and quantification of this relationship needs to be illustrated better. For example, in Figure 3, the microglia are shown at such low magnification that it is not possible to visualize their processes. Indeed, many of the images are quite small and make it hard to judge how effectively the authors are able to visualize and analyze individual microglial processes (Figure 1B, Ei-iii, Figure 2C, D and G, Figure 5D, Figure 6J)In each such example, the authors need to provide several examples of individual processes and a time series of images showing the fluorescence changes that accompany the morphological changes. In trying to address questions about the relationship between microglial calcium elevations and process motility, the authors should do more to demonstrate how tightly associated (or not) are calcium elevations and process extensions. In Figure 3H, they indicate that 48% of process extensions occur in the absence of detectable calcium elevation. This would seem to indicate that these two processes are somewhat independent of one another. However, is this percentage derived from cells that they are certain express GCaMP because they\'ve seen somatic or other process calcium elevations at some point during imaging? Or does this 48% include process extensions of cells that may not even express GCaMP? This same information (percentage of process extension/retraction/stable events that are associated with calcium elevations) should also be presented in the kainate (Figure 5) and DREADD (Figure 6) experiments. Figure 5F is potentially the most useful in showing whether there is a tight temporal relationship between process extension and calcium elevations. But we don\'t know if a similar temporal relationship is present in all processes that have both calcium elevations and extension or if there are also examples of processes that show extension and calcium elevations that are not temporally aligned. Can the authors show a similar panel to 5F for the isoflurane and DREADD experiments? For all instances of process extension accompanied by calcium elevations, can they quantify in some way the degree to which process extension and calcium elevations are temporally aligned and present this information?

5\) In trying to address questions about the relationship between microglial calcium elevations and neuronal activity, the authors should similarly provide additional analyses of how closely aligned in time are the two phenomena. In the isofluorane and DREADD experiments (Figure 3 and Figure 6), the 10-15 min long bins used for quantification make it challenging to understand how closely aligned in time are changes neuronal activity and changes in microglial calcium signaling. We appreciate that using smaller time bins may be challenging, but in the absence of more detailed information about the onset of detectable changes in neuronal activity and how this relates to the onset of detectable changes in microglial calcium signals, statements that \"microglia are attuned to changes in neuronal network activity\" are not well supported. Perhaps microglia are tuned to changes in astrocyte state and this is modified by shifts in neuronal network activity.

More detailed information about the temporal relationship between changes in neuronal activity and microglial calcium activity could help with speculating about mechanisms involved. Were the Ca^2+^ transients in microglial processes only observed when neuronal activity specifically changed from normal levels to enhanced/silent levels? Or, were Ca^2+^ transients observed when neuronal activity changed more generally between different levels, e.g. low to normal, high to normal, high to low? We believe that it would be sufficient to explore this question in an acute brain slice preparation where it might be easier to manipulate neuronal activity by employing receptor/channel reagents. At the very least, this issue should be discussed in more detail.

The authors investigated the long-term relationship between Ca^2+^ transients in microglia and neuronal activity (Figure 5), but they did not check the neuronal activity in these experiments. For how long does the increase in neuronal activity last after kainate administration? Would this increase in neuronal activity be sustained and constant or more sporadic in nature? Could the change in neuronal activity in fact be more temporary itself but yet still trigger a sustained, long-lasting increase in Ca^2+^ transients in microglia? To address these questions, it is necessary to monitor neuronal activity throughout the entire time course following kainate administration, e.g. by EEG or neuronal Ca^2+^ imaging etc.

6\) We need some indication about what the recombination efficiency is when giving tamoxifen in the diet as described. Otherwise, when presenting the percentage of microglial somas that exhibit calcium transients, we don\'t know if this is the percentage of GCaMP+ microglia that show spontaneous calcium elevations or if those cells that are \"inactive\" include cells that may not even express GCaMP.

7\) The Discussion is quite brief and does not include any comments on either the nature of the delay in microglial responses or the function of the dynamic changes in process extension in relation to the changes in neuronal activity. I recommend that this section be extended. In their discussion of possible mechanisms regulating microglial calcium signaling, can the authors also comment on whether these calcium signals are likely to be solely driven by influx of calcium through plasma membrane receptors versus supplemented or driven by release of calcium from intracellular stores? Can they tease out any difference in the dynamics or magnitude of microglial calcium signaling following network inhibition and network excitation that would support the idea of different mechanisms driving microglial calcium signals in each context?
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Author response

> Essential revisions:
>
> 1\) The authors used CX3CR1-CreER-ires-EYFP mice crossed with cre-dependent GCaMP6s and lck-GCaMP6f calcium indicators, and thus performed simultaneous imaging of EGFP and EYFP. Apparently, there was no attempt to split these signals -- due to their spectral overlap, it would be near impossible. As a result, the fluorescence changes reflect a combined GCaMP/EYFP signal. This needs to be clearly stated at the outset.

We thank the reviewers for the great comments and we have now clearly discussed the point.The initial studies did split the eYFP and GCaMP ('GFP') signals with a 'GFP/YFP' filter set (500/15 and 537/26). As shown theoretically with a spectral viewing program ([Author response image 1](#respfig1){ref-type="fig"}) and confirmed empirically, splitting the signal significantly attenuates GCaMP detection in the GFP channel (19% of total) and does not prevent spectral overlap (30% of the GCaMP signal collected in the YFP channel). On the other hand, maintaining both signals in one channel without attenuation (520/15 filter) preferentially detected GCaMP emission (estimated 45% of total potential emission, not shown) over eYFP emission (26% of total potential emission, not shown). The filter information has been added to the Materials and methods section. Additionally, we recently recorded laser power at the objective instead of along the laser path and updated those values in text to give a more accurate evaluation of the laser power at the cranial window. We have also added a statement about the combined GCaMP/eYFP signal in the text both immediately in the Results (subsection "Spontaneous microglial calcium activity reported in the Lck-GCaMP6f and cytosolic GCaMP6s mouse") and in the Discussion (subsection "The importance of microdomains in understanding glial calcium activity").

![Estimated collection efficiency of GCaMP6 and eYFP with a "GFP/YFP" filter set.\
Our initial approach to split these close spectra resulted in stronger GCaMP fluorescence in the YFP channel than the GFP channel and resulted in significant signal attenuation. Note that GCaMP6s was not an available fluorophore option, so GCaMP6f bound to calcium was used instead.](elife-56502-resp-fig1){#respfig1}

> As a result, the GCaMP signal to noise is reduced, so many smaller GCaMP fluctuations may have been missed. In the CX3CR1-CreER-ires-EYFP mice, the EYFP signal tends to be strongest in microglial somas -- will this then preferentially impact the ability to detect subtle changes in GFP signal within microglial somas? This issue should be discussed. If the authors have data from animals expressing GCaMP only, it would be helpful to include some of these data for comparison.

Yes. This does leave open the possibility for smaller fluctuations to be missed due to an artificially higher baseline (the F~0~ in our DF/F~0~). The potential under-reporting, particularly of smaller events has been discussed in the text (subsection "The importance of microdomains in understanding glial calcium activity"). Here we also concede that there is a potential bias for events in the soma to be particularly missed, but these events would need to be rapid and low amplitude. On the other hand, we also draw parallels between our work and other in vivo microglial calcium studies reaching similar conclusions about the rarity of somatic microglial calcium events (Eichhoff et al., 2011; Pozner et al., 2015).

Unfortunately, our mouse colony has historically kept the CX3CR1-CreER-IRES-eYFP line, not the CX3CR1-CreER line. Therefore, we do not have data from a mouse expressing GCaMP6s in microglia without the eYFP signal. However, we consider this a very important point and will be acquiring other microglia CreER lines soon to evaluate in future experiments.

> A second caveat with this approach is that all fluorescence fluctuations are interpreted as changes in intracellular calcium. Given the small size of these processes and their dynamic nature, there is concern that movements could also contribute to the fluctuations observed. This issue also needs to be discussed. Large scale coordination of events such as that shown in Figure 1E (Eii) raise concerns about such potential artefacts.

This is a key point. If we understand your question, we might restate it as 'any rapid movement in the x/y/z plane could result in a region of fluorescence moving in and out of the ROI, resulting in what erroneously appears as a calcium change.' We took the example of Figure 1E further to analyze this point and suggest the following: If there is a rapid shift in the focal plane in any direction, one would expect both a negative deflection (fluorescence moves out of the ROI, leading to a decrease in intensity reading) followed by a positive deflection (fluorescence moves back into the ROI, increasing the intensity reading). After subpixel registration, we do not see major decreases in fluorescence intensity, only positive increases ([Author response image 2](#respfig2){ref-type="fig"}). Further, we utilized the ImageJ registration plugin (Align Slices in Stack) for Figure 1E to tell us how much correction (in pixel distance) occurred from one frame to another. We plotted this pixel displacement as a proxy to quick shifts in the focal plane, presumably due to animal movements. This is plotted against the DF/F traces gathered in Figure 1E. We can see no clear correlation between shifts in the imaging frame and calcium events. The synchronized and coordinated calcium signals are hypothesized to reflect neuronal activity changes sensed by surrounding microglial processes. In the Discussion (subsection "Spontaneous microglial calcium activity and the utility of different GCaMP variants and preparations"), we discuss a potential hypothesis and future direction to study this phenomenon.

![Exploring movements and potential erroneous calcium detection.\
Adapted from Figure 1E, we do not see that frame-by-frame shifts (black line, pixel displacement detected by registration plugin) correlates with increases in calcium activity.](elife-56502-resp-fig2){#respfig2}

> 2\) It is surprising that the authors did not use automated detection algorithms to identify and quantify microglia calcium transients and define microglial movements. A number of such programs have been developed and are readily available.

We thank the reviewers for this important point of discussion. Multiple automated programs were tested over the past year for calcium detection.

1\) Inscopix data processing software: We first attempted to use the PCA/ICA package embedded in the Inscopix data processing software to automatically detect microglial process events after masking the soma region across all frames. We found this program often would overestimate or underestimate process size or create redundancies.

2\) Romano et al.'s computational toolbox:We also tried the Romano et al., 2017 program published in PLOS Computational Biology. Multiple processing steps in this toolbox were helpful, but ultimately, the user-guided parameters available for ROI detection were not ideal for detecting the complex shape of microglial processes (Romano et al., 2017).

3\) GECI Quant:Dr. Bal Khakh's GECI Quant program, an ImageJ-based detection program is ultimately very similar to our overall approach for process territory detection. GECI Quant first conducts frame-by-frame background subtraction, then has the user hand-segment somata, then has the user draw a bounding box around a territory of processes, which are detected at a user-defined threshold level. These steps generate threshold-based ROIs used in DF/F calculations. Our processing steps in finding process territories are very similar: (1) we created an average intensity projection, (2) hand-drew ROIs around somata, (3) used multi-measure to obtain soma intensity values for DF/F calculations, (4) masked these somata to better threshold processes, (5) threshold-selected processes with the analyze particles tool and added them to the ROI manager to create process territory ROIs, then (6) used multi-measure to obtain intensity values for these process territories used in DF/F calculations. We could have used GECI Quant in our analysis, except the data tabulation and program work-through is much slower than the simplified macros we created to preprocess data and obtain intensity values. Ultimately, we would argue that our process territory approach is reasonably similar to other programs that are considered semi-automated ROI detection approaches (Srinivasan et al., 2015).

> The method of ROI categorization needs to be described more thoroughly and higher magnification images shown to validate the approach. They should show an example image that indicates a typical soma ROI and typical process ROIs with corresponding ΔF/F traces for those ROIs. (Figure 2C shows one cell with arrows but doesn\'t show the actual ROIs with some kind of outline).

Yes, the Materials and methods section has been updated to more thoroughly explain the two different approaches to ROI selection (subsection "Calcium image processing and ROI selection"). We have created Figure 2---figure supplement 1 to address this question. In this figure, we expand upon Figure 2A to show 4 different microglia cells with highlighted soma and process ROIs alongside DF/F traces. This gives a better sense of the cell-to-cell variability and how hand-drawn ROIs were created. Additional examples of higher-magnification images were added to all figures.

> Without this information, there is confusion about what the ΔF/F traces represent. In Figures 1 and 2 -- are these soma and individual process ROIs from a single representative cell or multiple process ROIs from different cells across one field of view? In Figures 3 and 4 where \"process territory\" ROIs are used -- do the ΔF/F traces represent calcium signals in microglial processes in the entire field of view from different animals? Or process territories from different, individual microglial cells?

In Figures 1 and 2, ∆F/F traces are from the soma and processes of a single, representative cell. This has been updated in the figure legend.

In Figure 3D and Figure 4D, the microglial DF/F traces were created by the threshold-based ROI method and represent traces attributable to one representative cell, not a random selection of ROIs. For Figure 3E (heat map), the microglial process territories shown are all of the threshold-based process ROIs detected in different microglial cells from a single, representative animal across one experiment. The text of the figure legend has been updated to provide better clarification.

> What is the justification for examining individual process ROIs in Figures 1 and 2 but whole process territory ROIs in Figures 3 and 4?

In brief, the justification for using the two methods relates to perception over biased ROI selection. Automated segmentation of individual microglial processes is difficult due to their small size and tortuosity. Across multiple approaches, we found that no method to identify individual processes was as accurate as manual segmentation. In Figures 1 and 2, our purpose was to provide readers with characterization of process and soma calcium activity. We did not feel that this characterization presented strong cause for concern regarding bias, so we wanted to use the best approach we could employ. In Figures 3 and 4, we are testing whether an intervention like isoflurane or kainate alters microglial calcium activity. Herein, we wanted to avoid any concern that potential user bias in ROI selection could influence the results. For this reason, we used a threshold-based ROI selection technique to reduce user influence in ROI selection.

> In Figures 5 and 6 the ΔF/F traces are labeled with \"Processes\" so it\'s unclear if individual ROIs on distinct regions of processes were used as in Figures 1 and 2 or if process territories were used as in Figures 3 and 4.

Yes, these ROIs were generated through the threshold-based ROI approach and should be termed 'process territories.' This has been stated clearly in the figures and in the figure legend.

> 3\) In trying to address the question about what are the basic patterns of calcium activity in microglial cells, the authors miss an opportunity to provide additional, useful information using the images they have already acquired. Are the cells that show soma calcium elevations the same group of cells that show process elevations? Or can you sometimes see cells that have only soma calcium elevations or only process calcium elevations?

Thank you for bringing up this question. We have performed this analysis and added the results as Figure 2---figure supplement 1B. Microglia with somatic activity are not more likely to have process activity. Our results showed that about 25% of all microglia surveyed have soma and process calcium activity, while approximately 50% of microglia have process calcium activity without somatic calcium activity. Specifically, cells with only somatic calcium elevations are quite rare (\<5%). On the other hand, about 50% of microglia have process activity without somatic activity, so this represents the predominant pattern of activity.

> Of the cells that do show calcium elevations, are they scattered throughout the field of view or do they tend to be spatially clustered close to one another? What about these same questions following isoflurane, kainate, or DREADD manipulations?

In regards to spontaneous calcium activity in both acute and chronic window preparations, microglial cells with calcium activity are scattered throughout the field of view. With isoflurane application, at the peak of activity (10-30 minutes), increased calcium activity can be seen throughout the field of view, but some areas do represent 'hot spots' of dramatically increased activity. With kainate application during status epilepticus, or Gi/Gq activation, we observe similar results, where active cells are scattered throughout the field of view.

> Also -- if the mice are being imaged while on the NeuroTar air-lifted platform as described in the Materials and methods, can the authors comment about any relationship between microglial calcium elevations and ambulation or grooming?

This is a great question. Our current NeuroTar platform was an original version without magnetic location tracking. We will soon update our NeuroTar platform to have location tracking ability and plan to perform this experiment in the motor cortex. Similar to grooming, we found that deflecting whiskers evokes microglial calcium activity in the barrel cortex. However, these results are preliminary and we intend to utilize this approach to uncover the molecular mechanism behind this signal in the future. However, these results are preliminary and we intend to utilize this approach to uncover the molecular mechanism behind this signal in the future.

> 4\) One of the most interesting aspects of the work relates to linking process dynamics to changes in intracellular calcium. However, this phenomenon and quantification of this relationship needs to be illustrated better. For example, in Figure 3, the microglia are shown at such low magnification that it is not possible to visualize their processes. Indeed, many of the images are quite small and make it hard to judge how effectively the authors are able to visualize and analyze individual microglial processes (Figure 1B, Ei-iii, Figure 2C, D and G, Figure 5D, Figure 6J) In each such example, the authors need to provide several examples of individual processes and a time series of images showing the fluorescence changes that accompany the morphological changes.

We thank the reviewers for the great question. Here are the additional analysis to address the reviewers' concerns: For Figure 1B we added a zoomed-in image of a microglial cell with processes for both the Lck-GCaMP6f and cyto-GCaMP6s mouse. For Figure 1E, we did not perform process-based analyses and instead adopted a grid-based approach to describe the diffuse signal that largely originates in more parenchymal spaces. For Figure 2 panels, we created Figure 2---figure supplement 1 to demonstrate multiple microglia and the creation of manual ROIs to study their motility. For Figure 5D, we added a zoomed-in image of an individual cell. For Figure 6J, we created Figure 6---figure supplement 1 to highlight microglia processes.

We initially created time series images of processes (see Figure 3---figure supplement 1A and B) and attempted to inter-relate these images to expanded DF/F traces. However, we realized that doing this for all the requested figures with multiple examples for extension, retraction, or stable processes would take up a lot of figure space. We would kindly request to instead show such dynamics with videos, such as Figure 5---video 2 for the Figure 5 dataset. Additionally, motility and calcium can be viewed in Figure 3---video 1 for the isoflurane study and Figure 6---video 1 for the DREADD studies. However, we agree that better visualization of these phenomenon would improve the manuscript and we created multiple figure supplements to show a two-color image of extending, retracing, or stable processes and their calcium traces (Figure 3---figure supplement 1, Figure 5---figure supplement 2, Figure 6---figure supplement 1).

> In trying to address questions about the relationship between microglial calcium elevations and process motility, the authors should do more to demonstrate how tightly associated (or not) are calcium elevations and process extensions. In Figure 3H, they indicate that 48% of process extensions occur in the absence of detectable calcium elevation. This would seem to indicate that these two processes are somewhat independent of one another. However, is this percentage derived from cells that they are certain express GCaMP because they\'ve seen somatic or other process calcium elevations at some point during imaging? Or does this 48% include process extensions of cells that may not even express GCaMP? This same information (percentage of process extension/retraction/stable events that are associated with calcium elevations) should also be presented in the kainate (Figure 5) and DREADD (Figure 6) experiments.

Thanks for the great questions. This percentage has been derived from all cells/processes we could detect in the field of view. We did not include/exclude cells based upon whether any part of the cell had GCaMP activity. However, as explained in response to Question 6, we find that recombination is pretty high in our studies (at least 85%), so non-expression of GCaMP would not likely explain the \~50% of process extensions occurring without calcium activity. To address the reviewers' concerns, we have performed the additional analysis: The percentage of process extension/retraction/stable events associated with calcium elevations has been added for the kainate figure (Figure 5G) in place of the cumulative distribution plot. This has also been added for the Gi and Gq DREADD datasets (Figure 6K and L).

> Figure 5F is potentially the most useful in showing whether there is a tight temporal relationship between process extension and calcium elevations. But we don\'t know if a similar temporal relationship is present in all processes that have both calcium elevations and extension or if there are also examples of processes that show extension and calcium elevations that are not temporally aligned. Can the authors show a similar panel to 5F for the isoflurane and DREADD experiments? For all instances of process extension accompanied by calcium elevations, can they quantify in some way the degree to which process extension and calcium elevations are temporally aligned and present this information?

In addition to Figure 5F data, we have found a cleaner way to display this information with less figure space by highlighting the start and stop of extension/retraction overlaid with the DF/F trace (now Figure 5---figure supplement 2). This visualization approach was used for the isoflurane (Figure 3---figure supplement 1) and DREADD experiments (Figure 6---figure supplement 1).

We performed temporal analysis for the data one day after kainate status epilepticus (Figure 5H and Figure 5---figure supplement 2). In this dataset, we find that 51% of extending processes have a calcium event occurring within 1 minute of extension start, compared to 18% in retracting processes.

> 5\) In trying to address questions about the relationship between microglial calcium elevations and neuronal activity, the authors should similarly provide additional analyses of how closely aligned in time are the two phenomena. In the isofluorane and DREADD experiments (Figure 3 and Figure 6), the 10-15 min long bins used for quantification make it challenging to understand how closely aligned in time are changes neuronal activity and changes in microglial calcium signaling. We appreciate that using smaller time bins may be challenging, but in the absence of more detailed information about the onset of detectable changes in neuronal activity and how this relates to the onset of detectable changes in microglial calcium signals, statements that \"microglia are attuned to changes in neuronal network activity\" are not well supported. Perhaps microglia are tuned to changes in astrocyte state and this is modified by shifts in neuronal network activity.

This is a great suggestion. For the isoflurane experiments, we created Figure 3H to analyze process territory calcium signal area using one-minute bins. These values were then compared using a one-sample t-test to the average baseline period value to determine when significant changes in calcium signal area are first detected. We find significant process calcium activity above baseline is detected within 6 minutes after isoflurane exposure.

However, we began this analysis for the DREADD experiments and found it difficult to draw any sounder conclusions. In the isoflurane experiments, we know: (1) that there was a clear start time for neuronal silencing (within 1 minute after induction, Figure 3C); (2) that neuronal activity was consistently silenced across all animals (\~90%, Figure 3B-D); (3) that these results should be generalizable between cohorts. On the other hand: (1) DREADD-based effects take time to develop (progressive increase or decrease in activity, Figure 6D), while gas anesthetic action is near instantaneous; (2) variability in the time-of-peak effect exists between animals; (3) DREADD effects in the neuronal study cohort are broadly generalizable to the microglial study cohort, but probably cannot be used to draw firm minute-by-minute conclusions. After performing the minute-by-minute analysis, we still find that microglial calcium activity peaks approximately 15 minutes after the peak change in neuronal activity ([Author response image 3](#respfig3){ref-type="fig"}).

![Minute-by-Minute relationship between microglial calcium activity and neuronal activity changes.\
An example of breaking down neuronal calcium activity (top) into 3 min bins correlated with changes in microglial calcium activity. Neuronal calcium changes are significant as soon as 15 min after injection. Significant microglial changes are first detected 33 min after injection, suggesting a \~15 min latency between the two. These significant changes are sustained for the remainder of the recording.](elife-56502-resp-fig3){#respfig3}

The latency in the microglial response is a very important point for discussion and interpretation in regards to attunement to neuronal activity. We have dedicated a major section of our Discussion to this consideration (subsection "The relationship between neuronal activity changes, process extension, and process calcium signaling"). In addition, we agree that our results do not demonstrate a direct relationship between neuronal activity and microglial process signaling (i.e. real-time neurotransmitter release is the impetus for the observed microglial calcium signals). We have added this key point to the Discussion (subsection "The importance of microdomains in understanding glial calcium activity"). However, we also think it is important to consider that in DREADD-based experiments, neuronal activity changes are the start of a biological process that results in microglial calcium signaling increases.

> More detailed information about the temporal relationship between changes in neuronal activity and microglial calcium activity could help with speculating about mechanisms involved. Were the Ca^2+^ transients in microglial processes only observed when neuronal activity specifically changed from normal levels to enhanced/silent levels? Or, were Ca^2+^ transients observed when neuronal activity changed more generally between different levels, e.g. low to normal, high to normal, high to low? We believe that it would be sufficient to explore this question in an acute brain slice preparation where it might be easier to manipulate neuronal activity by employing receptor/channel reagents. At the very least, this issue should be discussed in more detail.

We thank the reviewers for this insightful point of consideration. This is indeed a current area of exploration in brain slices, representing a large undertaking to determine the mechanism(s) of microglial calcium signaling. Therefore, we would like to develop future projects that move from slice to an in vivo context exploring identified mechanisms. We discussed the question of state changes in relation to our current model (Discussion, subsection "The relationship between neuronal activity changes, process extension, and process calcium signaling"). Based upon our current work, we would hypothesize that state changes back to baseline may not trigger notable calcium elevations in microglia. These state changes are anticipated to involve more retraction than extension as microglia return to a less extended/surveilling state. Our work predicts that state changes engaging process retraction would not result in elevated calcium activity in microglia.

> The authors investigated the long-term relationship between Ca^2+^ transients in microglia and neuronal activity (Figure 5), but they did not check the neuronal activity in these experiments. For how long does the increase in neuronal activity last after kainate administration? Would this increase in neuronal activity be sustained and constant or more sporadic in nature? Could the change in neuronal activity in fact be more temporary itself but yet still trigger a sustained, long-lasting increase in Ca^2+^ transients in microglia? To address these questions, it is necessary to monitor neuronal activity throughout the entire time course following kainate administration, e.g. by EEG or neuronal Ca^2+^ imaging etc.

While we did not perform these experiments using neuronal calcium imaging or EEG, the first author has previously investigated the systemic kainate mouse model extensively using 24/7 video EEG (Umpierre et al., 2018, 2016). In his previously published studies, spectral analysis of cortical EEG from the parietal cortex indicates that neuronal activity broadly falls into three periods:

In the first 3 days after kainate status epilepticus, neuronal activity remains elevated. This could be considered evidence that more sustained elevations in neuronal activity occur in this period. EEG traces in this period commonly show interictal spiking as well as some sub-clinical (focal-cortical) seizure activity that does not secondarily generalize. These events could be considered more sporadic manifestations of coordinated neuronal activity increases.

Between 3-7 days after kainate status epilepticus, increased electrographic power begins to decrease and subclinical seizures are no longer observed; however, interictal spiking can persist, but normally at a reduced frequency.

Between 7-14 days after kainate status epilepticus, electrographic power is not noticeably increased. Interictal spiking is variable: persisting in some animals, gone in others, or manifesting sporadically over 24-72hr periods in others.

Spontaneous, generalized seizures are rare in the systemic kainate model and are not seen until 14 days after status epilepticus at earliest. Therefore, it is unlikely that spontaneous, epileptic seizures factored into the data. For multiple logistical reasons, it is very difficult to implant an EEG electrode in a mouse with a Neurotar headplate and retain this surgical assembly for many weeks, which is why we did not attempt to perform simultaneous, near-24/7 video EEG alongside longitudinal calcium imaging.

> 6\) We need some indication about what the recombination efficiency is when giving tamoxifen in the diet as described. Otherwise, when presenting the percentage of microglial somas that exhibit calcium transients, we don\'t know if this is the percentage of GCaMP+ microglia that show spontaneous calcium elevations or if those cells that are \"inactive\" include cells that may not even express GCaMP.

This is an important point that we initially intended to study; however, when we tried to design the experiment, we realized it could be quite difficult. In brief, the sequence similarity between eYFP and GCaMP (a circularly permutated GFP molecule) represented a strong concern for interpreting IHC data if antibodies detect a conserved epitope. If so, we could not tell all CX3CR1+ cells with constitutive eYFP expression from recombined cells with additional GCaMP expression.

Alternatively, we provide some evidence of recombination efficiency. We looked at the longitudinal study of microglial calcium activity following status epilepticus in chronic window animals (N=5). Our closest proxy to a positive control (similar to ATP application in culture or slice experiments) would be spreading wave calcium activity, where a large event propagates throughout the entire area of imaging (N=3/5 animals), or during the day of highest activity in the absence a wave (N=2/5 animals). To determine if a cell viably expressed GCaMP, we counted whether any part of a microglial cell exhibited calcium activity during these videos across all cells clearly identifiable in the area. After identifying cells with no activity, we also searched longitudinally through the dataset looking at other imaging days to determine if these non-active cells had an event on another day. Using this approach, we found that between 85-100% of microglia had a calcium response somewhere within the cell over multiple days ([Author response image 4](#respfig4){ref-type="fig"}; mean ± SEM: 89 ± 6%). This is decent evidence from a cohort of male and female mice that our recombination is likely strong.

![Longitudinal survey of active microglia in the kainate cohort.\
(Left) The survey method was used to observe any clear calcium event within any part of a cell (green outline) or confirm no observable event in the 15-minute recording (red outline). This example image can also be watched as Figure 5---video 1: Spreading Calcium Wave. In recordings from another day, the inactive cell (\#2, red outline) did show somatic calcium activity, suggesting the cell did have GCaMP expression when studied longitudinally. (Right) Percentage of microglia exhibiting calcium activity within one 300 x 300 µm region surveyed over six days (performed across N=5 mice).](elife-56502-resp-fig4){#respfig4}

> 7\) The Discussion is quite brief and does not include any comments on either the nature of the delay in microglial responses or the function of the dynamic changes in process extension in relation to the changes in neuronal activity. I recommend that this section be extended. In their discussion of possible mechanisms regulating microglial calcium signaling, can the authors also comment on whether these calcium signals are likely to be solely driven by influx of calcium through plasma membrane receptors versus supplemented or driven by release of calcium from intracellular stores? Can they tease out any difference in the dynamics or magnitude of microglial calcium signaling following network inhibition and network excitation that would support the idea of different mechanisms driving microglial calcium signals in each context?

Our manuscript was originally developed as a short report, leading to a shortened Discussion. We have expanded our Discussion to include the following topics: (1) discussion on the eYFP signal and how it impacts the study, (2) the nature of the delay in microglial responses and how it relates to motility and neuronal changes, (3) ionotropic versus metabotropic signaling mechanisms based upon previous in vivo work by others addressing this distinction, and (4) future directions and hypotheses regarding the Lck-GCaMP6f signal. Potential mechanisms are also discussed, which we are currently pursuing in brain slice.

In the Discussion, we mention other research (Eichhoff et al., 2011; Pozner et al., 2015) showing that both calcium influx pathways and intracellular calcium stores can be activated in vivoin microglia, but intracellular calcium stores appear to be more important for the injury responses studied in prior research. Based on the calcium signature observed in cytosolic-GCaMP6s microglia (including event size, spread, kinetics, and amplitude), we would have to posit that most of what we observe is consistent with intracellular store calcium. However, the calcium activity observed in the Lck-GCaMP6f mouse leaves open the possibility that this very rapid, small amplitude and diffuse calcium signature could potentially be calcium influx. We intend to test selective ionotropic and metabotropic receptor pharmacology in slice to discern the mechanism(s) for calcium elevations in microglia, but cannot give a definitive answer at this time.

Unfortunately, we cannot tease out any difference in the dynamics or magnitude of microglia calcium signaling after network inhibition or excitation. In DREADD-based experiments, approximately equal increases or decreases in neuronal calcium activity (i.e. a 31% decrease versus a 42% increase) results in very similar increases in microglial calcium signaling (64% versus 68% peak calcium signaling elevations) and have similar latencies. Thus, we do not detect major differences in the timing or magnitude of microglial calcium changes in response to reasonably equivalent shifts towards hyperactivity or hypoactivity.
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